Table 1 Clinical characteristics of subjects with rheumatoid arthritis (n = 119)
Demographics | Values |
|---|---|
Demographics | |
 Male sex | 19 (16%) |
 Age, years | 60.6 ± 13.4, 62.0 (53.5–70.5) |
 BMI, kg/m2 | 28.8 ± 6.3, 28.0 (25–32) |
Disease activity | |
 Seropositive RA** | 85 (71.4%) |
  RF+ (≥ 20) | 75 (63.0%) |
  CCP+ (≥ 20) | 59 (49.6%) |
 Disease duration, yr | 11.7 ± 9.6, 9.0 (5–16) |
 DAS28 | 2.7 ± 1.2, 2.6 (1.6–3.5) |
CV burden assessments | |
 Diabetes mellitus | 21 (17.6%) |
 Hypertension | 71 (59.7%) |
 Dyslipidemia | 56 (47.1%) |
 Prior CV disease history | 17 (14.3%) |
 Smoking (current) | 57 (47.9%) |
Medications | |
 Statin use | 32 (26.9%) |
 Steroid use | 54 (45.4%) |
 Methotrexate use | 64 (53.8%) |
 Biologic DMARD usea | 61 (51.3%) |
 Not currently receiving DMARDs | 11 (9.2%) |
 Antihypertensive drugsb | 55 (77.5%) |
  Diuretic | 29 (40.8%) |
  Calcium channel blocker | 21 (29.6%) |
  ACE inhibitor | 19 (26.8%) |
  β-Blocker | 18 (25.4%) |
  Angiotensin II receptor blockers | 13 (18.3%) |
  Vasodilator | 1 (1.4%) |
  α2-Adrenergic agonist | 1 (1.4%) |
Laboratory examination results | |
 ESR, mm/h | 21.3 ± 18.3, 14.5 (7–29.2) |
  > 15 mm/h | 45 (37.8%) |
  ≤ 15 mm/h | 47 (39.5%) |
  N/A | 27 (22.7%) |
 CRP (mg/dl) | 1.2 ± 2.6, 0.4 (0.2–0.9) |
  > 1 mg/dl | 22 (18.5%) |
  ≤ 1 mg/dl | 76 (63.9%) |
  N/A | 21 (17.6%) |